The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program

PD-L1 is a critical biomarker for a breakthrough therapy for NSCLC patients. Get educated on how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx.

The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:

  • Understand the core principles of PD-L1 pathology
  • Learn the process for evaluating stained images for PD-L1 expression
  • Recognize confounding considerations that affect PD-L1 interpretation
  • Score images for PD-L1 expression across a variety of patient samples

Get started

Already registered? LOGIN NOW
Intended Use
For in vitro diagnostic use.

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS ≥ 1% and high PD-L1 expression if TPS ≥ 50%.

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

3517 2016NOV18